SCHEMBL214688

SCHEMBL214688

CNCCC(C)CCCC(C)CCCC(C)CCCC(C)C

nearest known ligand 0.62

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.62
BLM P54132 1/20 0.45
PTPN1 P18031 3/20 0.39
MEN1 O00255 1/20 0.39
CYP3A4 P08684 1/20 0.39
ALOX15 P16050 1/20 0.39
KMT2A Q03164 1/20 0.39
KISS1R Q969F8 1/20 0.35
HTR2A P28223 2/20 0.32
HRH1 P35367 2/20 0.32
PTPN2 P17706 1/20 0.30
CDC25B P30305 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13362222 1.00 LMNA (0.62) LMNABLMPTPN1MEN1CYP3A4
SCHEMBL23094316 0.89 LMNA (0.54) LMNABLMPTPN1MEN1CYP3A4
SCHEMBL27371636 0.86 LMNA (0.64) LMNABLMPTPN1MEN1CYP3A4
SCHEMBL19646488 0.84 LMNA (0.39) LMNAKISS1RHTR2AHRH1
SCHEMBL21186540 0.84 KISS1R (0.42) LMNAKISS1RHTR2AHRH1
SCHEMBL21591959 0.84 HTR2A (0.40) LMNAKISS1RHTR2AHRH1
SCHEMBL24983926 0.83 LMNA (0.59) LMNABLMPTPN1MEN1CYP3A4
SCHEMBL277368 0.82 LMNA (0.65) LMNABLMPTPN1MEN1CYP3A4
SCHEMBL386434 0.81 EPHX1 (0.48) LMNA
SCHEMBL20928 0.81 LMNA (0.93) LMNABLMPTPN1MEN1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088395-B2 Phytol derived immunoadjuvants and their use in vaccine formulations INDIANA STATE UNIVERSITY (US) 2012-01-03 US claimed
US-20060292163-A1 PHYTOL DERIVED IMMUNOADJUVANTS AND THEIR USE IN VACCINE FORMULATIONS INDIANA STATE UNIVERSITY 2006-12-28 US claimed
US-20050158329-A1 Novel phytol derived immunoadjuvants and their use in vaccine formulations GHOSH SWAPAN K (US) 2005-07-21 US claimed
US-8088395-B2 Phytol derived immunoadjuvants and their use in vaccine formulations INDIANA STATE UNIVERSITY (US) 2012-01-03 US disclosed
US-20060292163-A1 PHYTOL DERIVED IMMUNOADJUVANTS AND THEIR USE IN VACCINE FORMULATIONS INDIANA STATE UNIVERSITY 2006-12-28 US disclosed
US-20050158329-A1 Novel phytol derived immunoadjuvants and their use in vaccine formulations GHOSH SWAPAN K (US) 2005-07-21 US disclosed
US-6417009-B1 COUPLING LIPID AUSTRALIAN MEMBRANE AND BIOTECHNOLOGY INSTITUTE (AU) 2002-07-09 US disclosed
EP-0912546-A1 IMPROVED RESERVOIR COMPONENTS AUSTRALIAN MEMBRANE AND BIOTECHNOLOGY RESEARCH INSTITUTE (AU) 1999-05-06 EP disclosed
WO-1997043274-A1 IMPROVED RESERVOIR COMPONENTS AUSTRALIAN MEMBRANE AND BIOTECHNOLOGY RESEARCH INSTITUTE (AU) 1997-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050158329-A1 Novel phytol derived immunoadjuvants and their use in vaccine formulations CD47, TSG101, LY96 LMNA 3976/4885BLM 1167/4885PTPN1 475/4885
US-20060292163-A1 PHYTOL DERIVED IMMUNOADJUVANTS AND THEIR USE IN VACCINE FORMULATIONS CD47, LY96, CD4 LMNA 3674/4885BLM 946/4885PTPN1 317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.